BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 31392631)

  • 1. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.
    Allen-Petersen BL; Sears RC
    BioDrugs; 2019 Oct; 33(5):539-553. PubMed ID: 31392631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A big step for MYC-targeted therapies.
    Atibalentja DF; Deutzmann A; Felsher DW
    Trends Cancer; 2024 May; 10(5):383-385. PubMed ID: 38580534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics.
    McAnulty J; DiFeo A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322239
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic targeting of "undruggable" MYC.
    Llombart V; Mansour MR
    EBioMedicine; 2022 Jan; 75():103756. PubMed ID: 34942444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC in oncogenesis and as a target for cancer therapies.
    Albihn A; Johnsen JI; Henriksson MA
    Adv Cancer Res; 2010; 107():163-224. PubMed ID: 20399964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attacking c-Myc: targeted and combined therapies for cancer.
    Huang H; Weng H; Zhou H; Qu L
    Curr Pharm Des; 2014; 20(42):6543-54. PubMed ID: 25341931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperine analogs arrest c-myc gene leading to downregulation of transcription for targeting cancer.
    Pandya N; Kumar A
    Sci Rep; 2021 Nov; 11(1):22909. PubMed ID: 34824301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long journey to bring a Myc inhibitor to the clinic.
    Whitfield JR; Soucek L
    J Cell Biol; 2021 Aug; 220(8):. PubMed ID: 34160558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC as a target for cancer treatment.
    Duffy MJ; O'Grady S; Tang M; Crown J
    Cancer Treat Rev; 2021 Mar; 94():102154. PubMed ID: 33524794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taking on challenging targets: making MYC druggable.
    Horiuchi D; Anderton B; Goga A
    Am Soc Clin Oncol Educ Book; 2014; ():e497-502. PubMed ID: 24857145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human MYC G-quadruplex: From discovery to a cancer therapeutic target.
    Wang W; Hu S; Gu Y; Yan Y; Stovall DB; Li D; Sui G
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188410. PubMed ID: 32827579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.
    Ahmadi SE; Rahimi S; Zarandi B; Chegeni R; Safa M
    J Hematol Oncol; 2021 Aug; 14(1):121. PubMed ID: 34372899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
    Savino M; Annibali D; Carucci N; Favuzzi E; Cole MD; Evan GI; Soucek L; Nasi S
    PLoS One; 2011; 6(7):e22284. PubMed ID: 21811581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative approaches to target Myc for cancer treatment.
    Wang C; Zhang J; Yin J; Gan Y; Xu S; Gu Y; Huang W
    Signal Transduct Target Ther; 2021 Mar; 6(1):117. PubMed ID: 33692331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Myc oncoprotein as a therapeutic target for human cancer.
    Vita M; Henriksson M
    Semin Cancer Biol; 2006 Aug; 16(4):318-30. PubMed ID: 16934487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
    Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
    Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
    Wang H; Teriete P; Hu A; Raveendra-Panickar D; Pendelton K; Lazo JS; Eiseman J; Holien T; Misund K; Oliynyk G; Arsenian-Henriksson M; Cosford ND; Sundan A; Prochownik EV
    Oncotarget; 2015 Oct; 6(32):32380-95. PubMed ID: 26474287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth.
    Pelengaris S; Khan M
    Expert Opin Ther Targets; 2003 Oct; 7(5):623-42. PubMed ID: 14498825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer.
    Li B; Simon MC
    Clin Cancer Res; 2013 Nov; 19(21):5835-41. PubMed ID: 23897900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic strategies to inhibit MYC.
    McKeown MR; Bradner JE
    Cold Spring Harb Perspect Med; 2014 Oct; 4(10):. PubMed ID: 25274755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.